A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Tislelizumab: Administered as part of routine clinical practice as determined by the treating physician in accordance with the summary of product characteristics (SmPC) and local standard of care
Study summary
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants are eligible to be included in the study only if they meet all the following criteria:
1. Participants or their legal representative must sign written inform consent form (ICF)
2. Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described.
Note: The decision to treat the patient with a tislelizumab-based regimen, as per its authorized indication, must have been made by the treating physician prior to and independent of the patient's consideration for participation in this study.
Exclusion Criteria:
* Participants are excluded from the study if they meet any of the following criteria:
1. Participants who are unable to understand all implications of study participation.
2. Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab.
3. Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.
Primary outcome measure(s)
Time from Diagnosis to First Dose — From date of first tislelizumab administration up to 30 months
Duration of Treatment — From date of first tislelizumab administration up to 30 months
Number of Participants with Dose Modifications — From date of first tislelizumab administration up to 30 months
Number of Participants with Treatment Discontinuation — From date of first tislelizumab administration up to 30 months
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
